Renata Patrícia Faria Maia

Ms. Renata Patrícia Faria Maia

University of Minho, Braga, Portugal
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Micromachines
Verified
Journal Article
Open access
PDF file
RMRenata Patrícia Faria Maia
Renata Patrícia Faria Maia
Violeta CarvalhoVioleta Carvalho
Violeta Carvalho
BFBernardo Faria
Bernardo Faria
IMInês Sofia Miranda
Inês Sofia Miranda
Susana O. CatarinoSusana O. Catarino
Susana O. Catarino
João RibeiroJoão Ribeiro
João Ribeiro
At the end of 2019, the coronavirus appeared and spread extremely rapidly, causing millions of infections and deaths worldwide, and becoming a global pandemic. For this reason, it became urgent and essential to find adequate tests for an accurate and fast diagnosis of this disease. In the present study, a systematic review was performed in order to provide an overview of the COVID-19 diagnosis methods and tests already available, as well as their evolution in recent months. For this purpose, the Science Direct, PubMed, and Scopus databases were used to collect the data and three authors independently screened the references, extracted the main information, and assessed the quality of the included studies. After the analysis of the collected data, 34 studies reporting new methods to diagnose COVID-19 were selected. Although RT-PCR is the gold-standard method for COVID-19 diagnosis, it cannot fulfill all the requirements of this pandemic, being limited by the need for highly specialized equipment and personnel to perform the assays, as well as the long time to get the test results. To fulfill the limitations of this method, other alternatives, including biological and imaging analysis methods, also became commonly reported. The comparison of the different diagnosis tests allowed to understand the importance and potential of combining different techniques, not only to improve diagnosis but also for a further understanding of the virus, the disease, and their implications in humans.

4 July 2025 in Materials Today Bio
Verified
Journal Article
Open access
ASAna Regina Sampaio
Ana Regina Sampaio
RMRenata Patrícia Faria Maia
Renata Patrícia Faria Maia
MCMaria Camilla Ciardulli
Maria Camilla Ciardulli
Hélder SantosHélder Santos
Hélder Santos
Bruno SarmentoBruno Sarmento
Bruno Sarmento
Nanoparticles (NPs) have unique properties, such as their high surface-to-volume ratio, nanoscale size, and functionalization potential, make them promising for a variety of biomedical applications, including drug delivery, diagnostics, and targeted therapy. With rapid progress in NPs research, increasing efforts are being made to develop new technologies for in vitro modeling and analysis of the efficacy and safety of nanotherapeutics in human physiological systems. Organ-on-chip (OoC) platforms are a cutting-edge alternative to traditional in vitro and in vivo models that provide a ground-breaking way to evaluate the toxicity and therapeutic efficacy of NPs. This review explores the advancements and achievements in OoC technology, focusing on explore the recent advances in healthy and diseases models and its potential to enhance NPs safety and efficacy. By simulating human biological systems, OoC help identify negative effects and mechanisms of action, reducing preclinical research failures and promoting targeted treatments. These platforms can cut down on drug development time and costs, making them invaluable for personalized medicine. However, challenges such as scalability and regulatory hurdles must be addressed before OoC can become a standard in NPs research and drug development. This review offers a critical and current summary of recent developments in OoC models for nanoformulation screening, emphasizing how they affect preclinical results and how they might be incorporated into the development of nanomedicine. It seeks to assist researchers and professionals in the industry in making well-informed choices regarding the use of these platforms.

28 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RMRenata Patrícia Faria Maia
Renata Patrícia Faria Maia
Violeta CarvalhoVioleta Carvalho
Violeta Carvalho
Rui A. LimaRui A. Lima
Rui A. Lima
Graca MinasGraca Minas
Graca Minas
RRRaquel Rodrigues
Raquel Rodrigues
Microneedles (MNs) have been widely used in biomedical applications for drug delivery and biomarker detection purposes. Furthermore, MNs can also be used as a stand-alone tool to be combined with microfluidic devices. For that purpose, lab- or organ-on-a-chip are being developed. This systematic review aims to summarize the most recent progress in these emerging systems, to identify their advantages and limitations, and discuss promising potential applications of MNs in microfluidics. Therefore, three databases were used to search papers of interest, and their selection was made following the guidelines for systematic reviews proposed by PRISMA. In the selected studies, the MNs type, fabrication strategy, materials, and function/application were evaluated. The literature reviewed showed that although the use of MNs for lab-on-a-chip has been more explored than for organ-on-a-chip, some recent studies have explored this applicability with great potential for the monitoring of organ models. Overall, it is shown that the presence of MNs in advanced microfluidic devices can simplify drug delivery and microinjection, as well as fluid extraction for biomarker detection by using integrated biosensors, which is a promising tool to precisely monitor, in real-time, different kinds of biomarkers in lab- and organ-on-a-chip platforms.

17 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
RMRenata Patrícia Faria Maia
Renata Patrícia Faria Maia
DRDiego A. Rodríguez
Diego A. Rodríguez
CSCatherine Sauders
Catherine Sauders
RFRafael V. M. Freire
Rafael V. M. Freire
JVJoop de Vries
Joop de Vries
Hélder SantosHélder Santos
Hélder Santos
Proteoliposomes are hybrid nanovesicles, combining membrane proteins and lipids to yield novel materials with promising biomedical applications. Precisely controlling the incorporation of membrane proteins while maintaining vesicle integrity is critical for the design of functional proteoliposomes. Here, we optimized a microfluidic method and identified flow rate ratio = 3 and total flow rate = 12 mL/min as the conditions that maximized protein incorporation into the proteoliposomes without disrupting phosphocholine or cholesterol signatures or colloidal stability of proteoliposomes. Single Particle Automated Raman Trapping Analysis revealed a clear, ratio dependent increase in protein associated bands and broader vesicle to vesicle heterogeneity at higher MPs loadings. Keeping the lipid:protein ratio constant revealed cell source–dependent differences in protein content, indicating that the membrane source strongly influences incorporation efficiency. Brain cancer-derived MPs exhibited the highest protein loading, whereas human dermal fibroblasts showed the lowest. Atomic force microscopy showed that protein rich nanovesicles displayed ~30–50% higher apparent stiffness and larger contact areas, while cryogenic transmission electro microscopy confirmed predominantly unilamellar morphology. Small angle X ray scattering demonstrated that membrane proteins act as structural regulators of the lipid bilayer, inducing cell source dependent remodelling without compromising vesicle integrity. These results identify independent variables for tuning proteoliposome composition and mechanical properties, enabling the rational design of bioinspired nanocarriers.